As of 2025-05-16, the Intrinsic Value of Genovis AB (GENO.ST) is 21.40 SEK. This GENO.ST valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 24.45 SEK, the upside of Genovis AB is -12.50%.
The range of the Intrinsic Value is 14.04 - 59.16 SEK
Based on its market price of 24.45 SEK and our intrinsic valuation, Genovis AB (GENO.ST) is overvalued by 12.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 14.04 - 59.16 | 21.40 | -12.5% |
| DCF (Growth 10y) | 18.33 - 77.35 | 28.01 | 14.6% |
| DCF (EBITDA 5y) | 19.92 - 32.77 | 26.92 | 10.1% |
| DCF (EBITDA 10y) | 23.86 - 41.83 | 32.97 | 34.9% |
| Fair Value | 12.57 - 12.57 | 12.57 | -48.59% |
| P/E | 11.34 - 20.45 | 16.54 | -32.4% |
| EV/EBITDA | 11.98 - 22.60 | 17.00 | -30.5% |
| EPV | 7.62 - 10.00 | 8.81 | -64.0% |
| DDM - Stable | 5.82 - 37.27 | 21.55 | -11.9% |
| DDM - Multi | 10.53 - 54.03 | 17.80 | -27.2% |
| Market Cap (mil) | 1,600.74 |
| Beta | 0.88 |
| Outstanding shares (mil) | 65.47 |
| Enterprise Value (mil) | 1,431.30 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.13% |
| Cost of Debt | 5.00% |
| WACC | 6.96% |